Keyword: Kymriah (tisagenlecleucel)
The cost of new cancer drug rollouts—$200,000 on average last year—is helping drive treatment costs toward $100 billion annually in the U.S. alone.
Gilead will locate the European manufacturing site for its CAR-T therapy Yescarta at a Netherlands airport to ensure quick turnaround for its patients.
If Novartis thought public statements this week would silence questions about its $1.2 million contract with Michael Cohen, it was wrong.
Gilead may have some exciting prospects ahead, but for now, its cash-cow hepatitis C business is a big drag. The good news? It's a 'trough year.'
If the competition between Novartis and Gilead in relapsed large B-cell lymphoma comes down to price, it will be a close race.
CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's requested add-on payment.
Our tournament mirrored the NCAA's this week, with No. 16 Giapreza sending home No. 1 Xiidra.
Drug spending in developed countries will fall this year, IQVIA says. The curbing effect? Rebates that more than offset pharma's price-hike haul.
A new analysis suggests Novartis could make a decent profit on Kymriah if the cost was just one-third its current price of $475,000.